Browse C5AR2

Summary
SymbolC5AR2
Namecomplement component 5a receptor 2
Aliases C5L2; GPR77; G protein-coupled receptor 77; GPF77; C5a anaphylatoxin chemotactic receptor C5L2; G protein-co ......
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Multi-pass membrane protein
Domain PF00001 7 transmembrane receptor (rhodopsin family)
Function

Receptor for the chemotactic and inflammatory C3a, C4a and C5a anaphylatoxin peptides and also for their dearginated forms ASP/C3adesArg, C4adesArg and C5adesArg respectively. Couples weakly to G(i)-mediated signaling pathways.

> Gene Ontology
 
Biological Process GO:0001818 negative regulation of cytokine production
GO:0002429 immune response-activating cell surface receptor signaling pathway
GO:0002430 complement receptor mediated signaling pathway
GO:0002526 acute inflammatory response
GO:0002673 regulation of acute inflammatory response
GO:0002683 negative regulation of immune system process
GO:0002685 regulation of leukocyte migration
GO:0002686 negative regulation of leukocyte migration
GO:0002688 regulation of leukocyte chemotaxis
GO:0002689 negative regulation of leukocyte chemotaxis
GO:0002697 regulation of immune effector process
GO:0002757 immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0002768 immune response-regulating cell surface receptor signaling pathway
GO:0002920 regulation of humoral immune response
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0006956 complement activation
GO:0006959 humoral immune response
GO:0007200 phospholipase C-activating G-protein coupled receptor signaling pathway
GO:0007204 positive regulation of cytosolic calcium ion concentration
GO:0009306 protein secretion
GO:0016485 protein processing
GO:0030336 negative regulation of cell migration
GO:0030449 regulation of complement activation
GO:0030593 neutrophil chemotaxis
GO:0030595 leukocyte chemotaxis
GO:0032102 negative regulation of response to external stimulus
GO:0032635 interleukin-6 production
GO:0032637 interleukin-8 production
GO:0032640 tumor necrosis factor production
GO:0032675 regulation of interleukin-6 production
GO:0032677 regulation of interleukin-8 production
GO:0032680 regulation of tumor necrosis factor production
GO:0032715 negative regulation of interleukin-6 production
GO:0032720 negative regulation of tumor necrosis factor production
GO:0038178 complement component C5a signaling pathway
GO:0040013 negative regulation of locomotion
GO:0043410 positive regulation of MAPK cascade
GO:0050663 cytokine secretion
GO:0050673 epithelial cell proliferation
GO:0050678 regulation of epithelial cell proliferation
GO:0050679 positive regulation of epithelial cell proliferation
GO:0050707 regulation of cytokine secretion
GO:0050708 regulation of protein secretion
GO:0050709 negative regulation of protein secretion
GO:0050710 negative regulation of cytokine secretion
GO:0050727 regulation of inflammatory response
GO:0050900 leukocyte migration
GO:0050920 regulation of chemotaxis
GO:0050922 negative regulation of chemotaxis
GO:0051048 negative regulation of secretion
GO:0051051 negative regulation of transport
GO:0051224 negative regulation of protein transport
GO:0051271 negative regulation of cellular component movement
GO:0051480 regulation of cytosolic calcium ion concentration
GO:0051604 protein maturation
GO:0055074 calcium ion homeostasis
GO:0060326 cell chemotaxis
GO:0070371 ERK1 and ERK2 cascade
GO:0070372 regulation of ERK1 and ERK2 cascade
GO:0070374 positive regulation of ERK1 and ERK2 cascade
GO:0070613 regulation of protein processing
GO:0071621 granulocyte chemotaxis
GO:0071622 regulation of granulocyte chemotaxis
GO:0071623 negative regulation of granulocyte chemotaxis
GO:0071706 tumor necrosis factor superfamily cytokine production
GO:0072376 protein activation cascade
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
GO:0072604 interleukin-6 secretion
GO:0072606 interleukin-8 secretion
GO:0090022 regulation of neutrophil chemotaxis
GO:0090024 negative regulation of neutrophil chemotaxis
GO:0097529 myeloid leukocyte migration
GO:0097530 granulocyte migration
GO:1900165 negative regulation of interleukin-6 secretion
GO:1902622 regulation of neutrophil migration
GO:1902623 negative regulation of neutrophil migration
GO:1903317 regulation of protein maturation
GO:1903531 negative regulation of secretion by cell
GO:1903555 regulation of tumor necrosis factor superfamily cytokine production
GO:1903556 negative regulation of tumor necrosis factor superfamily cytokine production
GO:1904950 negative regulation of establishment of protein localization
GO:1990266 neutrophil migration
GO:2000146 negative regulation of cell motility
GO:2000257 regulation of protein activation cascade
GO:2000482 regulation of interleukin-8 secretion
Molecular Function GO:0001847 opsonin receptor activity
GO:0004875 complement receptor activity
GO:0004878 complement component C5a receptor activity
Cellular Component GO:0009925 basal plasma membrane
GO:0016323 basolateral plasma membrane
GO:0045177 apical part of cell
GO:0045178 basal part of cell
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-373076: Class A/1 (Rhodopsin-like receptors)
R-HSA-166658: Complement cascade
R-HSA-500792: GPCR ligand binding
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-375276: Peptide ligand-binding receptors
R-HSA-977606: Regulation of Complement cascade
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
Summary
SymbolC5AR2
Namecomplement component 5a receptor 2
Aliases C5L2; GPR77; G protein-coupled receptor 77; GPF77; C5a anaphylatoxin chemotactic receptor C5L2; G protein-co ......
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between C5AR2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolC5AR2
Namecomplement component 5a receptor 2
Aliases C5L2; GPR77; G protein-coupled receptor 77; GPF77; C5a anaphylatoxin chemotactic receptor C5L2; G protein-co ......
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of C5AR2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolC5AR2
Namecomplement component 5a receptor 2
Aliases C5L2; GPR77; G protein-coupled receptor 77; GPF77; C5a anaphylatoxin chemotactic receptor C5L2; G protein-co ......
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of C5AR2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.3140.125
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.4530.24
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2110.52
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1380.815
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.9110.375
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.8510.543
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0120.982
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.5590.491
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.6190.467
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.9890.147
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.7640.0465
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.5720.00874
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of C5AR2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolC5AR2
Namecomplement component 5a receptor 2
Aliases C5L2; GPR77; G protein-coupled receptor 77; GPF77; C5a anaphylatoxin chemotactic receptor C5L2; G protein-co ......
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of C5AR2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolC5AR2
Namecomplement component 5a receptor 2
Aliases C5L2; GPR77; G protein-coupled receptor 77; GPF77; C5a anaphylatoxin chemotactic receptor C5L2; G protein-co ......
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of C5AR2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by C5AR2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolC5AR2
Namecomplement component 5a receptor 2
Aliases C5L2; GPR77; G protein-coupled receptor 77; GPF77; C5a anaphylatoxin chemotactic receptor C5L2; G protein-co ......
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of C5AR2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolC5AR2
Namecomplement component 5a receptor 2
Aliases C5L2; GPR77; G protein-coupled receptor 77; GPF77; C5a anaphylatoxin chemotactic receptor C5L2; G protein-co ......
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of C5AR2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolC5AR2
Namecomplement component 5a receptor 2
Aliases C5L2; GPR77; G protein-coupled receptor 77; GPF77; C5a anaphylatoxin chemotactic receptor C5L2; G protein-co ......
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between C5AR2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolC5AR2
Namecomplement component 5a receptor 2
Aliases C5L2; GPR77; G protein-coupled receptor 77; GPF77; C5a anaphylatoxin chemotactic receptor C5L2; G protein-co ......
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting C5AR2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.